About us Contacts Drug interactions: 390 212
Drug search by name

Ambrisentan and Kaletra

Determining the interaction of Ambrisentan and Kaletra and the possibility of their joint administration.

Check result:
Ambrisentan <> Kaletra
Relevance: 13.12.2023 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Ritonavir may increase the blood levels and effects of ambrisentan. This can increase the risk of serious side effects such as liver damage, anemia, and fluid accumulation (particularly in the lungs). You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Contact your doctor immediately if you experience fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, dark colored urine, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage. Also seek medical attention if you develop paleness, dizziness, fainting, swelling, unusual weight gain, difficulty breathing, and/or shortness of breath. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

MONITOR: In vitro data suggest that coadministration with potent inhibitors of P-glycoprotein (e.g., cyclosporine) and/or organic anion transporting polypeptide (e.g., cyclosporine, ritonavir) may increase the plasma concentrations of ambrisentan, which is a substrate of these transporters. In healthy volunteers, steady-state coadministration of ambrisentan and cyclosporine resulted in a 2-fold increase in ambrisentan exposure. The interaction has not been studied with other P-gp or OATP inhibitors.

MANAGEMENT: Because ambrisentan is associated with dose-related hepatotoxicity, concomitant use with potent inhibitors of P-gp and/or OATP should be approached with caution. Patients should be advised to notify their physician if they experience signs and symptoms of liver injury such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice.

References
  • "Product Information. Letairis (ambrisentan)." Gilead Sciences, Foster City, CA.
Ambrisentan

Generic Name: ambrisentan

Brand name: Letairis

Synonyms: n.a.

Kaletra

Generic Name: lopinavir / ritonavir

Brand name: Kaletra

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction